Xencor's Growing Confidence in Its In-House Pipeline
Xencor is increasingly optimistic about its in-house pipeline, which could lead to significant advancements in drug development and attract investor interest.
Editorial Staff 2 days ago
#pharmaceuticals
15 articles tagged with "pharmaceuticals"
Ironwood: Linzess Provides Temporary Relief Amid Apraglutide's Valuation Challenges
Ironwood Pharmaceuticals is navigating a complex landscape as Linzess offers short-term benefits, but Apraglutide's rNPV fails to close the valuation gap, raising investor concerns.
Editorial Staff 3 days ago
Aldeyra Therapeutics: Navigating the Challenges After Reproxalap's Third CRL
Following the third Complete Response Letter for Reproxalap, Aldeyra Therapeutics is at a crossroads. This article explores the potential paths forward for the company.
Editorial Staff 6 days ago
Federal Court Blocks Colorado's Price Cap on Enbrel by Amgen
A federal judge has intervened to stop Colorado's initiative to impose a price cap on Enbrel, a major drug produced by Amgen, raising questions about state-level drug pricing regulations.
Editorial Staff 15 days ago
Innovative Use of Table Sugar May Transform Drug Development
Recent research suggests that table sugar and vinegar could be used to create affordable carbohydrate-based medicines, potentially replacing expensive treatments for common ailments.
Editorial Staff 17 days ago
Unraveling the Secrets Behind Eli Lilly’s Obesity Drug
Eli Lilly's obesity drug has garnered significant attention, raising questions about exclusive access and the motivations behind pharmaceutical acquisitions.
Editorial Staff 22 days ago
European Nations Navigate Drug Pricing Challenges Amid U.S. Influence
As the U.S. observes the situation, European countries are developing varied approaches to drug pricing, which could have significant implications for the pharmaceutical sector and patient access.
Editorial Staff about 1 month ago
Increased Scrutiny for Telehealth Prescribers and Lilly's Compounding Concerns
Telehealth prescribers are now under heightened scrutiny following FDA warnings about compounded weight loss drugs, while Lilly is actively opposing certain compounding practices.
Editorial Staff Updated about 2 months ago
FDA Delays Decision on AstraZeneca's Breast Cancer Treatment Following Panel Vote
The FDA has postponed its decision on AstraZeneca's experimental breast cancer pill after an advisory panel voted against its approval, signaling further review is needed.
Editorial Staff about 2 months ago
Takeda Settles for $13.6 Million Over Alleged Kickbacks to Physicians
The pharmaceutical giant Takeda Pharmaceuticals has agreed to a $13.6 million settlement concerning allegations of providing kickbacks to doctors for prescribing its antidepressant.
Editorial Staff 2 months ago
Pharmaceutical Lobbying Sees Significant Increase; Bristol-Myers Forms New Partnership in China
Pharmaceutical companies have ramped up their lobbying efforts, spending over $130 million in 2025, while Bristol-Myers Squibb has announced a new partnership with a Chinese firm.
Editorial Staff 2 months ago
France's ANSM Takes Action Against Novo Nordisk and Eli Lilly for Misleading Advertising
The ANSM has imposed sanctions on Novo Nordisk and Eli Lilly for running promotional campaigns disguised as public awareness efforts, raising concerns about ethical advertising practices.
Editorial Staff 2 months ago